Recursion Pharmaceuticals (RXRX) Cash & Equivalents (2020 - 2026)

Recursion Pharmaceuticals has reported Cash & Equivalents for 7 years, with the latest figure at $654.5 million in Q1 2026.

• For the quarter ending Q1 2026, Cash & Equivalents rose 30.78% year-over-year to $654.5 million; the trailing twelve-month figure through Mar 2026 stood at $654.5 million (up 30.78% YoY), and the FY2025 full-year result was $743.3 million, up 25.06% from the prior year.
• Cash & Equivalents for Q1 2026 stood at $654.5 million, down from $743.3 million in the prior quarter.
• The five-year high for Cash & Equivalents was $743.3 million in Q4 2025, with the low at $296.3 million in Q1 2024.
• Historically, Cash & Equivalents has averaged $500.0 million across 5 years, with a median of $474.3 million in 2024.
• Annual changes were most pronounced in 2022 — Cash & Equivalents jumped 137.23% — and 2024, when it sank 37.37%.
• Recursion Pharmaceuticals' Cash & Equivalents stood at $549.9 million in 2022, then dropped by 28.79% to $391.6 million in 2023, then soared by 51.79% to $594.4 million in 2024, then climbed by 25.06% to $743.3 million in 2025, then retreated by 11.95% to $654.5 million in 2026.
• The last three Cash & Equivalents figures came in at $654.5 million (Q1 2026), $743.3 million (Q4 2025), and $659.8 million (Q3 2025), per Business Quant data.